Skip to main content
S&P 5007,580.07-1.82%DOW51,770.31-1.09%NASDAQ25,437.00-2.86%BTC$77,415.00+0.36%ETH$2,246.32+1.22%GOLD$3,884.90-3.63%OIL$102.95+0.93%
Smart Investors Daily
SID Premium
RE

NASDAQ · REPL

Replimune Group, Inc.

Healthcare · Biotechnology

$17.61

Up+$0.22 (+1.27%)

Updated Nov 1, 2026, 4:14 PM

SID Score

6.0/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
774.6M
P/E ratio
-3.23
Dividend yield
0.00%
52-week range
$1.50 – $18.27
Volume
3.85M
Avg. volume
5.08M

Price performance · REPL

REPL price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 30, 2026

REPL closed at $17.61 after 20 trading sessions, up 33.92% for the selected period.

Last close
$17.61
Period change
+33.92%
Period low
$10.86
Period high
$17.61
Daily close
View OHLC price history
REPL OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 30, 2026$17.49$18.2735$16.635$17.613.85M
Oct 29, 2026$16.27$17.78$16.195$17.395.15M
Oct 28, 2026$12.96$16.75$12.50$16.067.28M
Oct 27, 2026$12.45$13.16$12.2065$13.054.3M
Oct 26, 2026$11.56$12.57$11.36$12.472.05M
Oct 23, 2026$11.92$11.92$11.43$11.461.91M
Oct 22, 2026$11.70$12.01$11.5293$11.991.76M
Oct 21, 2026$11.37$12.045$11.31$11.722.2M
Oct 20, 2026$11.04$11.69$10.995$11.421.39M
Oct 19, 2026$11.03$11.225$10.67$11.051.54M
Oct 16, 2026$11.73$11.73$10.805$10.861.71M
Oct 15, 2026$11.32$11.86$11.2314$11.751.61M
Oct 14, 2026$12.05$12.37$11.37$11.391.86M
Oct 13, 2026$12.91$12.93$12.07$12.111.63M
Oct 12, 2026$13.21$13.56$12.97$13.071.16M
Oct 9, 2026$12.96$13.44$12.79$13.422.02M
Oct 8, 2026$13.18$13.46$12.85$13.041.75M
Oct 7, 2026$13.14$13.60$13.01$13.201.65M
Oct 6, 2026$13.17$13.51$12.87$13.252.62M
Oct 5, 2026$13.14$13.29$12.51$13.152.28M

Latest REPL news

The latest Smart Investors Daily articles mentioning REPL.

Stock researchCompany · Overview

REPL research

Overview

Company profile and research snapshot.

Company profile

Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$13.67
Implied upside
—
Analysts
—
REPL recent ratings
DateFirmRatingTarget
Oct 29, 2026Leerink PartnersOutperform—
Aug 26, 2026JP MorganOverweight—
Aug 7, 2026JP MorganOverweight—
Aug 7, 2026WedbushOutperform—
Aug 4, 2026Leerink PartnersOutperform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 22, 2026

Replimune to Report the Fiscal Second Quarter 2027 Financial Results and Provide Corporate Update on October 28, 2026

WOBURN, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a commercial stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that it will host a conference call on Wednesday, October 28, 2026, at 8:00 a.m. ET to discuss its financial results and provide corporate update for the fiscal second quarter ended September 30, 2026. Listeners can register for the webcast via this link. Analysts wishing to participate in th

Yahoo · Oct 17, 2026

Replimune Group (REPL) Stock Looks Rich After A 141% Run

Replimune Group has seen its share price move sharply in recent years, which naturally puts the spotlight on what the current US$10.86 level really represents. The key issue for you as a shareholder or potential buyer is whether that price still lines up with what the balance sheet and book value can support. Replimune Group is up 141.3% over the past year, so anyone looking at the stock today has to ask if that kind of move is backed by the assets and equity on the books. The business model...

Yahoo · Oct 9, 2026

Replimune Group (REPL) Launches TUDRIQEV As Its Valuation Story Comes Into Focus

Replimune Group (REPL) has reached an inflection point, with TUDRIQEV now commercially available in the US for adults with advanced cutaneous melanoma who progressed on prior anti-PD-1 treatment. Replimune Group’s launch of TUDRIQEV comes after a sharp reset in the short term, with the 30 day share price return down 11.71%, even as the 90 day share price return is up 18.65% and the 1 year total shareholder return is very large at 181.64%. This suggests that momentum has cooled recently...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By